338 related articles for article (PubMed ID: 25813704)
1. Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.
Bordia T; McGregor M; McIntosh JM; Drenan RM; Quik M
Neuroscience; 2015 Jun; 295():187-97. PubMed ID: 25813704
[TBL] [Abstract][Full Text] [Related]
2. Role for α6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice.
Quik M; Park KM; Hrachova M; Mallela A; Huang LZ; McIntosh JM; Grady SR
Neuropharmacology; 2012 Sep; 63(3):450-9. PubMed ID: 22579614
[TBL] [Abstract][Full Text] [Related]
3. The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release.
Bordia T; McIntosh JM; Quik M
J Neurochem; 2013 Apr; 125(2):291-302. PubMed ID: 23373725
[TBL] [Abstract][Full Text] [Related]
4. α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.
Quik M; Campos C; Bordia T; Strachan JP; Zhang J; McIntosh JM; Letchworth S; Jordan K
Neuropharmacology; 2013 Aug; 71():191-203. PubMed ID: 23583932
[TBL] [Abstract][Full Text] [Related]
5. Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitization.
Bordia T; Campos C; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2010 Jun; 333(3):929-38. PubMed ID: 20200117
[TBL] [Abstract][Full Text] [Related]
6. Nicotine reduces L-DOPA-induced dyskinesias by acting at beta2* nicotinic receptors.
Huang LZ; Grady SR; Quik M
J Pharmacol Exp Ther; 2011 Sep; 338(3):932-41. PubMed ID: 21665941
[TBL] [Abstract][Full Text] [Related]
7. Multiple CNS nicotinic receptors mediate L-dopa-induced dyskinesias: studies with parkinsonian nicotinic receptor knockout mice.
Quik M; Campos C; Grady SR
Biochem Pharmacol; 2013 Oct; 86(8):1153-62. PubMed ID: 23831952
[TBL] [Abstract][Full Text] [Related]
8. Nicotinic receptor agonists reduce L-DOPA-induced dyskinesias in a monkey model of Parkinson's disease.
Zhang D; Mallela A; Sohn D; Carroll FI; Bencherif M; Letchworth S; Quik M
J Pharmacol Exp Ther; 2013 Oct; 347(1):225-34. PubMed ID: 23902940
[TBL] [Abstract][Full Text] [Related]
9. Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats.
Huang LZ; Campos C; Ly J; Ivy Carroll F; Quik M
Neuropharmacology; 2011 May; 60(6):861-8. PubMed ID: 21232546
[TBL] [Abstract][Full Text] [Related]
10. The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
Thornton E; Hassall MM; Corrigan F; Vink R
Parkinsonism Relat Disord; 2014 May; 20(5):508-13. PubMed ID: 24637127
[TBL] [Abstract][Full Text] [Related]
11. ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease.
Zhang D; Bordia T; McGregor M; McIntosh JM; Decker MW; Quik M
Mov Disord; 2014 Apr; 29(4):508-17. PubMed ID: 24515328
[TBL] [Abstract][Full Text] [Related]
12. Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Gerlach M; Bartoszyk GD; Riederer P; Dean O; van den Buuse M
J Neural Transm (Vienna); 2011 Dec; 118(12):1733-42. PubMed ID: 21253782
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
[TBL] [Abstract][Full Text] [Related]
14. Amelioration of L-Dopa-Associated Dyskinesias with Triterpenoic Acid in a Parkinsonian Rat Model.
Ndlovu BC; Daniels WM; Mabandla MV
Neurotox Res; 2016 Jan; 29(1):126-34. PubMed ID: 26459303
[TBL] [Abstract][Full Text] [Related]
15. AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.
Di Paolo T; Grégoire L; Feuerbach D; Elbast W; Weiss M; Gomez-Mancilla B
Parkinsonism Relat Disord; 2014 Nov; 20(11):1119-23. PubMed ID: 25172125
[TBL] [Abstract][Full Text] [Related]
16. Nicotine-mediated improvement in L-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function.
Quik M; Mallela A; Chin M; McIntosh JM; Perez XA; Bordia T
Neurobiol Dis; 2013 Feb; 50():30-41. PubMed ID: 23009753
[TBL] [Abstract][Full Text] [Related]
17. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
[TBL] [Abstract][Full Text] [Related]
18. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Kobylecki C; Crossman AR; Ravenscroft P
Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
[TBL] [Abstract][Full Text] [Related]
19. Role for the nicotinic cholinergic system in movement disorders; therapeutic implications.
Quik M; Zhang D; Perez XA; Bordia T
Pharmacol Ther; 2014 Oct; 144(1):50-9. PubMed ID: 24836728
[TBL] [Abstract][Full Text] [Related]
20. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]